Abstract
Triple negative breast cancer has recently been recognized as a distinct subtype of breast cancer. While TNBC and basal-type breast cancers are not identical, the terms are often used synonomously. TNBC have a poorer prognosis than other molecular subtypes of breast cancer. There are no known targeted agents, leaving chemotherapy as the primary adjuvant therapy. TNBC are associated with BRCA1 mutations, are more common in African-American women, and have a more aggressive clinical course, with high early rates of metastatic disease and early relapse. Current research is examining epidemiologic features associated with TNBC, and searching for effective targeted therapy.
Keywords: Triple negative breast cancer, basal-type breast cancer, racial/ethnic differences in breast cancer
Call for Papers in Thematic Issues
RARE CASES IN GYNECOLOGY-OBSTETRICS
With the development of diagnostic and therapeutic techniques (such as ART techniques) and the immersion of new pathologies (such as COVID19), we are witnessing an increase in the incidence of pathologies that were previously described as rare or exceptional. the practitioner sometimes confronts difficult situations in these cases in diagnostic ...read more
6